Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022

GlobeNewswire February 16, 2022

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

GlobeNewswire January 26, 2022

Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR(TM) Technology

GlobeNewswire January 11, 2022

Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

GlobeNewswire January 10, 2022

Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T(TM) Clinical Trials

GlobeNewswire January 10, 2022

Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation

GlobeNewswire December 15, 2021

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T(TM) Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

GlobeNewswire December 13, 2021

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin's Lymphoma at the 63rd Annual Meeting of the American Society of Hematology

GlobeNewswire December 13, 2021

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

GlobeNewswire December 1, 2021

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

GlobeNewswire November 12, 2021

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  

GlobeNewswire November 4, 2021

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T(TM) Trials at the 63rd Annual Meeting of the American Society of Hematology

GlobeNewswire November 4, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

PR Newswire November 4, 2021

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

GlobeNewswire October 28, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

PR Newswire October 15, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

Newsfile October 8, 2021

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

GlobeNewswire October 7, 2021

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

GlobeNewswire September 20, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

GlobeNewswire September 1, 2021